Form 4: Co-Diagnostics Director Reports Stock Transactions

Richard S. Serbin, a Director at Co-Diagnostics, Inc., reported a transaction involving the acquisition of 1,695 shares of common stock on May 23, 2026.

Summary

• Richard S. Serbin, a Director at Co-Diagnostics, Inc. (CODX), reported a transaction on May 23, 2026.
• The transaction involved the acquisition of 1,695 shares of common stock.
• These shares were acquired at a price of $0.00, indicating they were likely part of a restricted stock unit award.
• Following this transaction, Serbin beneficially owns 10,751 shares of common stock directly.
• The filing also details restricted stock units awarded on June 12, 2023, April 26, 2024, and August 13, 2025, which vest over time.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine disclosure of insider stock transactions related to compensation rather than a significant strategic event or change in financial performance.

Positives

• Director Richard S. Serbin acquired 1,695 shares of common stock, indicating continued investment or compensation in the company.
• The acquisition was at $0.00, suggesting it was part of a long-term incentive plan, aligning management interests with shareholders.

Future Outlook

The filing details the vesting schedules for restricted stock units awarded in 2023, 2024, and 2025, indicating future potential share issuances or ownership changes as these units vest over time.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. These filings are crucial for investors seeking to understand insider sentiment and potential alignment with shareholder interests.

Stakeholder Impact

• Shareholders: Increased transparency into director's holdings and compensation structure.
• Management: Reinforces alignment of interests through equity-based compensation.

Next Steps

• Continued vesting of restricted stock units awarded on June 12, 2023, April 26, 2024, and August 13, 2025, according to their respective schedules.

Key Dates

Keywords

Co-Diagnostics, CODX, Form 4, SEC Filing, Insider Transaction, Director, Common Stock, Restricted Stock Units, Beneficial Ownership